EGFR and lung carcinoma: Recently, molecular therapeutics targeting receptor tyrosine kinase (RTK) aberrations in lung cancer, including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), and immunotherapies have been developed.1